

Chairman's Message

Dear Shareholders, dear Business Partners,

The progress and achievements in life sciences and the biopharmaceutical industry have probably never been more apparent to everyone than they have been over the past two years. Rapid development and production of highly effective vaccines against coronavirus are an impressive demonstration of the high impact that the innovative power of this industry has on people's health worldwide.

Key therapies, such as the treatment of various types of cancer, have been based on biotechnological manufacturing processes for quite some time now. While monoclonal antibodies have been playing the most significant role for some years, promising progress has recently been made in the development of new modalities. In this context, I would like to particularly highlight cell and gene therapeutic methods as well as mRNA-based approaches and other innovative technologies. Thanks to such new opportunities, we can expect further breakthroughs in the treatment of diseases that so far have been difficult to cure or even incurable, giving hope to millions of patients.

Sartorius Stedim Biotech is focused on providing its customers in the biopharmaceutical industry as well as at biotech startups and in science the tools and technologies to achieve such breakthroughs, enabling researchers and engineers to reach their goals faster and at lower costs. The pandemic has made the relevance of our portfolio in this regard very evident.

In fiscal 2021, we contributed to making the production of newly developed coronavirus vaccines at an unparalleled speed and in unprecedented quantities a reality. Still, pandemic-related business was a relevant, but not a dominant factor in the past year as our core business generated even higher contributions to growth. Sales revenue rose by around 53% to around €2.89 billion, and we also achieved a further increase in profitability with an operating EBITDA margin of 35.8%. This development was driven by strong growth and new record highs in basically all product segments and in all geographies.

Managing this strong growth was only possible due to the significant increase in headcount and our very extensive investment program to expand production capacities. I am happy that the Sartorius Stedim Biotech team has increased by more than 2,800 people and closed 2021 with more than 10,400 employees. Investments were used to expand our capacities in several product segments and in all business regions.

Over the past months, we also closed a series of strategic acquisitions. With the takeover of Xell and the acquisition of a majority stake in CellGenix, we further expanded our product portfolio that is especially important for manufacturing cell and gene therapeutics as well as vaccines. In early 2022, we completed the acquisition of the Novasep chromatography division that had already been agreed upon at the beginning of 2021.

A brief word on our stock market performance: Sartorius Stedim Biotech shares closed 2021 with a gain of around 66%. In addition to the company's business performance and its attractive growth prospects, the above-average valuation factors in the biotech and life science sectors had an amplifying effect.



During the past years, we have already implemented various measures to reduce our ecological footprint. Now we have set an ambitious target to continuously reduce our CO₂ emission intensity by around 10% annually. By 2030, this is projected to lower our emission intensity by almost 70%. Over time, we will spend around 1% of Group sales revenue per year to reach this ambitious goal.

Let's now take a look at the future: The long-term trends and main drivers of our business remain strong, and the global biopharma sector is currently in a highly dynamic and innovative phase. At the same time, the pandemic is not over yet, and even short-term forecasts are subject to relatively high uncertainty. In this environment, we project that consolidated sales revenue will increase by about 15% to 19% this year and – following the jump in profitability in 2021 – expect our underlying EBITDA margin to reach more than 35% in 2022. We are continuing to move ahead at full speed in investing in additional capacities and are planning with a CAPEX ratio of around 14.5%.

Regarding our mid-term targets, we are now aiming to achieve an underlying EBITDA margin of more than 35% in 2025, a level around two percentage points higher than predicted before. Our sales revenue target continues to be projected at around €4 billion, and we plan to achieve it primarily through organic growth and additionally by acquisitions. These targets do not include any pandemic-related business as it is currently not possible to make a robust estimate of this.

We can reach these ambitious goals only as a team. In the past year, our employees went all the extra miles so that we could supply our customers reliably with urgently needed products. Our special thanks therefore go out to the entire international Sartorius Stedim Biotech team for their extraordinary performance yet again.

I would also like to sincerely thank you, our valued customers, business partners, and shareholders. Based on the trust you have placed in us – often throughout many years – you have contributed significantly to the positive development of Sartorius Stedim Biotech. We would be pleased if you would continue to accompany us in 2022 and beyond and share in the further success of our company.

Sincerely,

A handwritten signature in blue ink, appearing to read 'JK', written in a cursive style.

Joachim Kreuzburg
Chairman of the Board and CEO



Board of Directors

Board of Directors

The Board of Sartorius Stedim Biotech is the central management and supervisory entity of the company, and is composed of eight members. The directors are appointed for a three-year term.



Joachim Kreuzburg
Chairman | CEO



Pascale Boissel



Chrystel Baudere



Susan Dexter



René Fáber



Anne-Marie Graffin



Lothar Kappich



Henri Riey

Sartorius Stedim Biotech Shares

Facts about the Share ¹

ISIN	FR0013154002
Liquidity provider	Kepler Cheuvreux
Stock exchange	Euronext Paris
Market segment	Local Securities - Compartment A (Large Caps)
Indexes	SBF 120; CAC Next 20; CAC Large 60; CAC All-Tradable; CAC All Shares; CAC Healthcare; STOXX Europe 600; MSCI France
Number of shares	92,180,190
thereof Sartorius AG	73.8%
thereof free float	26.2%
Voting rights	160,526,383
thereof Sartorius AG	84.8%
thereof free float	15.2%

¹ As of December 31, 2021


Stock Markets Post Price Gains

International stock markets reported major price rises in the reporting year against a background of strong economic recovery and increasing corporate profits. Various risk factors, such as strained global supply chains, high rates of price increases for raw materials and preliminary products, and a supply shortage in some sectors, only occasionally resulted in setbacks. A possible end to expansionary monetary policy because of higher-than-expected inflation rates likewise hit sentiment on the markets only temporarily. Important benchmark indices reached new all-time highs in 2021. The Dow Jones ended the reporting year at 36,338 points, having gained 18.7%. The MSCI Europe closed around 19.9% higher at 1,935 points. The French benchmark index CAC 40 and the CAC Large 60, which includes the Sartorius Stedim Biotech shares, also reached new highs, with the CAC 40 rising by 28.9% to 7,153 points and the CAC Large 60 by 27.1% to 7,806 points.


Sartorius Stedim Biotech Shares Rise Sharply

The Sartorius Stedim Biotech share price was volatile, but developed very positively overall during the reporting year. Contributing factors included better-than-expected business performance, several associated forecast adjustments, and the completion of two acquisitions. The news regarding the coronavirus pandemic and the shift from growth to cyclical stocks triggered by rising interest on U.S. government bonds also impacted the performance of Sartorius Stedim Biotech shares. The company's shares reached an all-time high of €548.2 on September 10, 2021, and closed the stock-market year somewhat lower at €482.4 – up 65.7% year over year.

Sartorius Stedim Biotech Share in €
January 1, 2017 to December 31, 2021



Sartorius Stedim Biotech Share in Comparison to the CAC Large 60 and MSCI Europe Index (indexed)
January 1, 2021 to December 31, 2021



Investor Relations Activities

Sartorius Stedim Biotech's investor relations activities follow the objective of making the current and future development of the company transparent for its stakeholders. To achieve this objective, the company maintains an ongoing, open dialog with shareholders, potential investors and financial analysts.

Besides providing quarterly, first-half and annual reports, we inform the capital market and the interested public at quarterly teleconferences and in regularly published press releases about the current development of our business and other material events at the company. Moreover, Group management and the IR team made themselves available to capital market participants at mostly virtual conferences and roadshows.

All information and publications relating to our company and its shares are provided on our website at www.sartorius.com.

Analysts

The recommendations of financial analysts serve as a foundation for the decisions of private and institutional investors when investing in shares. Currently, ten institutions regularly prepare reports and updates on Sartorius Stedim Biotech shares.

Research Coverage


Date	Institute	Price target in €	Recommendation
January 31, 2022	J.P. Morgan	550.00	Buy
January 28, 2022	Exane BNP Paribas	510.00	Buy
January 28, 2022	Société Générale	510.00	Buy
January 27, 2022	ODDO BHF	530.00	Buy
January 27, 2022	Kepler Cheuvreux	500.00	Buy
January 27, 2022	UBS	297.00	Sell
January 27, 2022	Morningstar	290.00	--
October 28, 2021	Berenberg	544.00	Buy
October 25, 2021	AlphaValue	451.00	Sell
July 21, 2021	Gilbert Dupont	455.00	Buy

Dividends

The total return generated by Sartorius Stedim Biotech shares has generally been based almost entirely on the positive development of the share price and only to a very small extent on dividend payments. In line with the rapid and highly innovation-driven development of our industry, the main focus of company's management is on successfully continuing on our dynamic profitable growth track and on making the extensive investments in capacity expansions, innovations and acquisitions that are constantly required for this purpose. Yet within this context, Sartorius Stedim Biotech strives to enable its shareholders to participate appropriately in the company's success through dividends.

The Board of Directors will submit a proposal to the Annual Shareholders' Meeting on March 29, 2022, to pay dividends of €1.26 per share from the underlying net profit of €687.8 million for fiscal 2021, up from the previous year's figure of €0.68. If this proposal is approved, the total profit distributed would be €116.1 million (2020: €62.7 million). The corresponding dividend payout ratio would be 16.9%, compared to the prior-year ratio of 16.3%.

Dividends in €



¹ The original dividend proposal of €0.68 per share was adjusted in light of the pandemic crisis

² Amount suggested by the Board of Directors and subject to approval by the Annual General Shareholders' Meeting

Total Shareholder Return


Total shareholder return considers both the dividends paid out and any share price increases over a certain period, and thus reflects the entire performance of an investment. In 2021, Sartorius Stedim Biotech shares delivered a TSR of 65.9%, compared to 97.4% a year earlier.

Shareholder Structure

Sartorius Stedim Biotech S.A.'s issued capital amounted to €18.4 million as of December 31, 2021, and was divided into 92,180,190 shares, each with a calculated par value of €0.20. As some of the shares confer double voting rights, there were 160,526,383 voting rights in total as of the reporting date.

As of December 31, 2021, Sartorius AG has held 73.8% of the Stedim Biotech S.A.'s share capital and 84.8% of the voting rights outstanding. The remaining 26.2% of Stedim Biotech S.A. shares are in free float, corresponding to 15.2% of the voting rights outstanding.

Shareholding Structure in % of share capital



Key Figures for Sartorius Stedim Biotech Share

		2021	2020	2019	2018	2017
Share price ¹ in €	Reporting date	482.40	291.20	147.70	87.35	60.29
	High	548.20	357.60	149.20	119.80	72.49
	Low	287.60	143.00	83.30	60.35	51.50
Dividends ² in €		1.26	0.68	0.34	0.57	0.46
Total dividends paid ² in millions of €		116.1	62.7	31.3	52.5	42.4
Dividend yield ³ in %		0.3	0.2	0.2	0.7	0.8
Market capitalization in millions of €		44,467.7	26,842.9	13,615.0	8,051.9	5,557.5
Average daily trading number of shares		52,717	70,414	63,935	80,140	52,753
Trading volume of shares in millions of €		5,524.1	4,234.6	2,037.8	1,874.9	818.2
CAC Large 60 (closing prices of the year)		7,806	6,144	6,598	5,246	5,871
SBF 120 (closing prices of the year)		5,546	4,432	4,704	3,756	4,251

1 Daily closing price

2 For 2021, amounts suggested by the Board of Directors and subject to approval by the Annual General Shareholders' Meeting

3 Dividends in relation to the corresponding closing prices of the year

Sources: Euronext; NASDAQ